The association between neovascular age-related macular degeneration and regulatory T cells in peripheral blood
Authors Madelung C, Krüger Falk M, Sørensen TL
Received 3 February 2015
Accepted for publication 17 March 2015
Published 25 June 2015 Volume 2015:9 Pages 1147—1154
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 4
Editor who approved publication: Dr Scott Fraser
Christopher Fugl Madelung,1,2 Mads Krüger Falk,1,2 Torben Lykke Sørensen1,2
1Clinical Eye Research Unit, Department of Ophthalmology, Copenhagen University Hospital, Roskilde, Denmark; 2University of Copenhagen, Copenhagen, Denmark
Purpose: To investigate regulatory T cells (Tregs) and subsets of the Treg population in patients with neovascular age-related macular degeneration (AMD).
Patients and methods: Twenty-one neovascular AMD cases and 12 age-matched controls without retinal pathology were selected. Patients were recruited from our outpatient retinal clinic. Control individuals were typically spouses. The diagnosis of neovascular AMD was confirmed using fluorescein and indocyaningreen angiography. Fresh venous blood was analyzed by flow cytometry using fluorochrome-conjugated antibodies to the Treg surface antigens CD4, CD25, CD127, CD45RA, and CD31. Main outcome measures were the percentage of CD25highCD127low Tregs, the percentage of CD45RA+ naïve Tregs, and the percentage of CD31+ recent thymic emigrant Tregs.
Results: Comparing patients with neovascular AMD to controls, no significant differences were found in the percentages of CD4+ lymphocytes, CD25highCD127low Tregs, CD45RA+ naïve Tregs, or CD31+ recent thymic emigrant Tregs.
Conclusion: Our data does not indicate an altered state of systemic Treg cells in neovascular AMD.
Keywords: Tregs, macular degeneration, immunosenescence, CD45RA antigens, CD31 antigens
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]